Understanding SARS-CoV-2-Mediated Inflammatory Responses: From

Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.

COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies

Viruses, Free Full-Text

Eje Renina Angiotensina, Enzima Convertidora de Angiotensina 2 y Coronavirus

Innate immunological pathways in COVID-19 pathogenesis

SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders - ScienceDirect

Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Covid-19 Effects on organs

Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC)

COVID-19 therapeutics: Challenges and directions for the future